The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS announced a strategic collaboration that combines SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and scientific expertise to accelerate data-driven cancer care through tools that analyze, interpret and translate diagnostic results into clinical practice.
Under the partnership, the organizations will launch a series of research and development programs and co-develop an advanced next-generation sequencing oncology test. Built on the SOPHiA DDM™ Platform’s AI algorithms, the test aims to translate complex multimodal data into actionable insights with greater speed and scale. MD Anderson researchers will leverage SOPHiA GENETICS’ AI to create bioinformatics pipelines that enable clinicians to rapidly interpret complex RNA-sequencing data to guide cancer diagnosis and treatment.
“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” said Donna Hansel, M.D., Ph.D., division head of Pathology and Laboratory Medicine at MD Anderson. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”
MD Anderson and SOPHiA GENETICS will jointly pursue programs to characterize tumor evolution in real time, strengthen the reliability and reproducibility of complex genomic testing, and improve identification of optimal clinical trials or research avenues for individual patients. The multi-layered initiative is intended to fuel next-generation scientific discovery and give clinicians and researchers tools to better understand cancer’s dynamic nature. The collaborative work at MD Anderson will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor in the Division of Pathology and Laboratory Medicine.
“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” said Philippe Menu, M.D., Ph.D., chief product officer and chief medical officer at SOPHiA GENETICS. “With SOPHiA DDM™ as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”
Leave a Reply